Verus Capital Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.61M Buy
1,346
+390
+41% +$398K 0.09% 144
2026
Q1
$879K Sell
956
-151
-14% -$153K 0.06% 184
2025
Q4
$1.19M Sell
1,107
-52
-4% -$49.7K 0.08% 154
2025
Q3
$884K Sell
1,159
-6
-0.5% -$4.46K 0.07% 161
2025
Q2
$908K Sell
1,165
-153
-12% -$119K 0.08% 147
2025
Q1
$1.09M Sell
1,318
-224
-15% -$186K 0.11% 121
2024
Q4
$1.19M Sell
1,542
-34
-2% -$28.2K 0.11% 116
2024
Q3
$1.4M Buy
1,576
+72
+5% +$64.7K 0.14% 99
2024
Q2
$1.36M Buy
1,504
+224
+18% +$179K 0.14% 102
2024
Q1
$996K Buy
1,280
+60
+5% +$42.7K 0.11% 118
2023
Q4
$711K Sell
1,220
-54
-4% -$31.5K 0.09% 133
2023
Q3
$684K Sell
1,274
-229
-15% -$118K 0.1% 126
2023
Q2
$705K Buy
1,503
+321
+27% +$135K 0.1% 121
2023
Q1
$406K Buy
1,182
+111
+10% +$37.4K 0.06% 180
2022
Q4
$392K Buy
1,071
+184
+21% +$65.2K 0.07% 175
2022
Q3
$287K Buy
887
+147
+20% +$46.6K 0.05% 207
2022
Q2
$239K Buy
740
+1
+0.1% +$300 0.05% 244
2022
Q1
$218K Buy
+739
New +$190K 0.03% 289
2020
Q1
$135K Sell
970
-573
-37% -$78.7K 0.04% 253
2019
Q4
$203K Buy
+1,543
New +$179K 0.07% 234

Other funds holding LLY

Verus Capital Partners's LLY Position: Q2 2026 in Review

Verus Capital Partners increased its Eli Lilly (LLY) stake by 41% in Q2 2026, buying an estimated $398K and bringing the position to 1,346 shares worth $1.61M. The position accounts for 0.09% of the portfolio, ranked #144.

Verus Capital Partners first reported a position in LLY in Q4 2019 and has held it in 20 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Verus Capital Partners held 1,346 shares of Eli Lilly worth $1.61M as of Q2 2026.
  • Verus Capital Partners bought 390 Eli Lilly shares in Q2 2026, an estimated $398K.
  • Eli Lilly made up 0.09% of Verus Capital Partners's portfolio in Q2 2026, its #144 holding.
  • Verus Capital Partners first reported a position in Eli Lilly in Q4 2019 and has held it in 20 quarters since.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.